tbuckley/cabot-search huggingface dataset:
Survival comparison analysis of two historical cohorts of metastatic renal cell carcinoma patients (cytokine therapy vs. targeted agents): A European single-center experience over 26 years.
Authors: Georg C. Hutterer, Silvia V. Golbeck, Edvin Mrsic, Daniel Krieger, Angelika Bezan, Karl Pummer, Richard Zigeuner, Martin Pichler
Journal: Journal of Clinical Oncology (2015)

e15617 Background: By the approval of new targeted agents in 2006, the standard of therapy in metastatic renal cell carcinoma (mRCC) changed, since they demonstrated significantly improved progression-free survival (PFS) rates compared with interferon in phase-3 clinical trials. Differences in overall survival (OS) could not be proven since many patients switched to another effective substance after progression of the disease. Thus, we compared two mRCC patient cohorts in order to detect OS differences between immunotherapy and targeted therapies in a real-life population outside controlled clinical trials. Methods: Clinico-pathological data from 594 mRCC patients, operated between 1984 and 2010 at a single tertiary academic center, were evaluated retrospectively with the null hypothesis, that there is no statistically significant difference in OS of patients treated either with interferon or targeted agents. Using electronical patient records, all data regarding the beginning, the duration, the lines and different forms of therapies were assessed. Patients’ cancer-specific survival (CSS), as well as OS were assessed using the Kaplan-Meier method, compared with the log-rank test. A first analysis revealed results for the entire study cohort. Subsequently, outcome analyses were restricted to mRCC patients with clear cell histology only. Results: With respect to the complete follow-up period, our results in both analyses did not show a statistically significant OS difference between the two therapy modalities. By limiting the observation period to 5 years after treatment initiation, a statistically significantly improved median five-year OS rate (26 mo.) for clear cell mRCC patients treated with targeted agents was observed, compared with 21 mo. in the interferon group (p= 0.028). Conclusions: Our results confirm the presumption of an improved OS in mRCC attributable to treatments with targeted agents compared with previous cytokine therapies.
The safety and tolerability of veliparib (V) plus capecitabine (C) and radiation (RT) in subjects with locally advanced rectal cancer (LARC): Results of a phase 1b study.
Authors: Brian G. Czito, Mary Frances Mulcahy, William R. Schelman, Houman Vaghefi, Gayle S. Jameson, Angela Deluca, Hao Xiong, Wijith Munasinghe, Matthew W. Dudley, Kyle D. Holen, Michael Michael
Journal: Journal of Clinical Oncology (2014)

3634 Background: Patients (pts) with LARC treated with neoadjuvant RT/C and then surgery have significant relapse rates with low rates of complete response. V is a potent, orally bioavailable PARP inhibitor that has been shown to enhance the efficacy of chemotherapy and RT in preclinical models. This study sought to establish the recommended phase 2 dose (RPTD) as well as to assess safety, pharmacokinetics (PK), and preliminary activity of V + RT/C in pts with LARC. Methods: Pts with stage II-III rectal cancer received RT (50.4Gy/1.8Gy/fraction) with C (825 mg/m2BID) five days per week (W) for 5.5W. Dosing of V (BID, 20mg-400mg) continued from W1D2 to 2 days past RT. Pts underwent surgery 5-10W following RT. Assessments include identification of RPTD with the Exposure Adjusted Continual Reassessment Method, adverse events (AEs), PK, and pathological response: no disease present on pathologic review (ypCR), microscopic disease only (yCR), and tumor downstaging. Results: As of Dec 8, 2013, 18 pts have been enrolled, 12/6 male/female, median age 55 yrs; 1 pt discontinued due to an AE. The most common treatment-emergent AEs (>20% pts, n ≥ 4) were diarrhea (39%), nausea (39%), fatigue (33%), radiation skin injury (33%), dysuria (22%), and constipation (22%). One Grade 3/4 event of diarrhea and one post-operative event of anastomosis dehiscence were deemed at least possibly related to V. One dose limiting toxicity (DLT) occurred at 70mg BID V (radiation skin injury requiring dose interruption); 1 pt at 400 mg BID described ongoing intolerable nausea not meeting the criteria of a DLT. The RPTD is 400 mg V in combination with RT/C. PK results from 16 pts suggest that V PK was approximately dose proportional when administered with RT/C and that V had no effect on the PK of C. To date, 11/15 (73%) pts have been downstaged post-surgery; with 4/16 (25%) ypCR and 4/16 (25%) yCR. Conclusions: V at 400 mg in combination with RT/C has an acceptable safety profile, and the combination will move forward in an expanded cohort to better define toxicity and efficacy. Escalations of V resulted in approximately dose proportional increases in the V PK with no clear effect on C PK. Clinical trial information: NCT01589419.
Understanding Cardiology
Authors: E. N. Coomes
Journal: Annals of the Rheumatic Diseases (1980)

This method of presentation means that difficult to get an overall picture of a disea For example, the changes found in hyperti monary oesteoarthropathy may be found se the sections on the foot, the hand, and knee, b is there an overall description of the condil sequently one is left with the impression tha monest changes are a periostitis of the bc hand and feet, and the more common perio: forearms and ankles is not stressed.Similarly
Drug Combo Beneficial in Colorectal Cancer
Journal: Cancer Discovery (2014)

Abstract Patients with BRAF-mutant colorectal cancer respond poorly, if at all, to BRAF inhibitors such as vemurafenib. Research has shown that this is likely due to rapid feedback activation of EGFR, and investigators are exploring dual suppression of BRAF and EGFR, with or without PI3K inhibition, as a new therapeutic avenue.
THE DEVELOPMENTAL CYCLES OF THE ORGANISM OF MALARIA.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Dose-Intensive Melphalan With Blood Stem-Cell Support for the Treatment of AL (Amyloid Light-Chain) Amyloidosis: Survival and Responses in 25 Patients
Authors: Raymond L. Comenzo, Evan Vosburgh, Rodney H. Falk, Vaishali Sanchorawala, Johann Reisinger, Simon Dubrey, Laura M. Dember, John L. Berk, Gorgun Akpek, Michael LaValley, Carl O'Hara, Charles F. Arkin, Daniel G. Wright, Martha Skinner
Journal: Blood (1998)
Brown tumor of the orbit
Authors: N. J. Holzer
Journal: JAMA (1977)

BROWN tumor arising in the retroorbital region has not, to our knowledge, been previously reported. We report the case of a woman with chronic renal failure and a rapidly progressive proptosis with loss of visual acuity secondary to orbital brown tumor. <h3>Report of a Case</h3> A 24-year-old woman receiving long-term hemodialysis, with a four-year history of renal failure secondary to glomerulonephritis, was admitted to Montefiore Hospital on July 30, 1976, complaining of rapidly progressive proptosis of the right eye (OD), right-sided headaches, decrease in visual acuity, and right facial numbness. She had a 12-mm proptosis of the right eye, with severe reduction in extraocular motion in all directions. Visual acuity was 20/70 OD, and 20/25 in the left eye. A Marcus-Gunn pupil was present in the right eye. Funduscopic examination showed striking choroidal folds in the posterior pole of the right eye. Hypesthesia was present in the right infraorbital nerve
HABITUAL ENDORSERS OF NOSTRUMS.
Journal: JAMA (1891)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Question
Authors: CARL SPIVACK
Journal: Annals of Internal Medicine (1980)

Ad Libitum1 June 1980The QuestionCARL SPIVACK, M.D.CARL SPIVACK, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-92-6-864 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptA man lay in bed, days away from death. His skin white and his lips dry, the man rested beneath the sheets. Relatives gathered at his side. He spoke to them in a whistling, gasping voice. They bent over, their ears almost to his lips to hear him. They fed him chips of ice and moistened his face. They whispered to him. When the doctor arrived—a weary man, grey and balding—the relatives moved away from the bed. The doctor too bent down to hear the muted words the man spoke. The man whispered a question into the doctor's ear. Why,... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: New York, New York PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 June 1980Volume 92, Issue 6Page: 864-864 Issue Published: 1 June 1980 PDF DownloadLoading ...
What's wrong with the ERISA vacuum? Employers' freedom to limit health care coverage provided by risk retention plans
Authors: L. O. Gostin
Journal: JAMA (1993)

THROUGHOUT the political campaigns waged during 1992, health care for Americans was one of the major issues. Candidates repeatedly expressed concern for the 30 to 65 million individuals who are not insured or who have inadequate coverage for their health care needs.<sup>1</sup>Ironically, as the fall election campaigns were concluding, the Supreme Court of the United States was deliberating on whether to hear an appeal from a decision of the Fifth Circuit Court of Appeals<sup>2</sup>that may result in more individuals being cast into the ranks of the uninsured or inadequately insured. Just a few days after Americans elected a presidential candidate committed to providing universal health care, the Supreme Court—with two justices dissenting—decided not to accept an appeal,<sup>2,3</sup>by the executor of the estate of John McGann, from the lower court judgment, which allowed an employer to reduce health care benefits radically for one of its
In Vivo Molecular Imaging of Somatostatin Receptors in Pancreatic Islet Cells and Neuroendocrine Tumors by Miniaturized Confocal Laser-Scanning Fluorescence Microscopy
Authors: C. Fottner, E. Mettler, M. Goetz, E. Schirrmacher, M. Anlauf, D. Strand, R. Schirrmacher, G. Klöppel, P. Delaney, M. Schreckenberger, P. R. Galle, M. F. Neurath, R. Kiesslich, M. M. Weber
Journal: Endocrine Reviews (2010)

The aim of the study was to evaluate real time in vivo molecular imaging of somatostatin receptors (sstrs) using a handheld miniaturized confocal laser scan microscope (CLM) in conjunction with fluorescein-labeled octreotate (OcF) in healthy mice and murine models of neuroendocrine tumors. For CLM a small rigid probe (diameter 7 mm) with an integrated single line laser (488 nm) was used (optical slice thickness 7 μm; lateral resolution 0.7 μm). OcF was synthesized via Fmoc solid-phase peptide synthesis and purified by HPLC showing high-affinity binding to the sstr2 (IC50 6.2 nmol). For in vitro evaluation, rat and human pancreatic cancer cells were used and characterized with respect to its sstr subtype expression and functional properties. For in vivo confocal imaging, healthy mouse pancreatic islet and renal tubular cells as well as immunoincompetent nude mice harboring sstr-expressing tumors were evaluated. Incubation of sstr-positive cells with OcF showed a specific time- and dose-dependent staining of sstr-positive cells. CLM showed rapid internalization and homogenous cytoplasmatic distribution. After systemic application to mice (n = 8), specific time-dependent internalization and cytoplasmatic distribution into pancreatic islet cells and tubular cells of the renal cortex was recorded. After injection in tumor-harboring nude mice (n = 8), sstr-positive cells selectively displayed a cell surface and cytoplasmatic staining. CLM-targeted biopsies detected sstr-positive tumor cells with a sensitivity of 87.5% and a specificity of 100% as correlated with ex vivo immunohistochemistry. CLM with OcF permits real-time molecular, functional, and morphological imaging of sstr-expressing cell structures, allowing the specific visualization of pancreatic islet cells and neuroendocrine tumors in vivo.
Efficacy and safety of antidepressants for children and adolescents
Journal: BMJ (2004)

group, 4 but another study showed that virtual groups may be less effective than face to face groups to sustain weight loss. 13In terms of the outcome measures used, future studies should also include measures of resource use, as it is currently not clear whether participation in a peer to peer group reduces or increases the use of health care.Given the abundance of unmoderated peer to peer groups on the internet, researchers must focus their efforts not only on sophisticated professionally led systems, but shift their attention to consumer led, self help venues.Perhaps in this way the research community can best help consumers to help themselves, a guiding principle of support groups regardless of the venue in which they occur.
Keyword Index — Volumes 71+72
Journal: Cardiovascular Research (2006)

ABCA1 (72) 473 Acidification (71) 754 Action potentials (71) 430 Adenosine (72) 292 Adenosine deaminase (71) 79 Adenosine receptor (71) 79 Adipose tissue (71) 363 Adrenergic agonists (71) 108 Adrenergic (ant) agonists (71) 430 Adrenergic antagonist (71) 537 a 1A -adrenergic receptor (71) 735 Adrenergic receptors (71) 69 Ageing (72) 9 Aldosterone (71) 300 AMD3100 (71) 455 Amine oxidase (72) 349 Angiogenesis (71) 158, (71) 226, (72) 394 Angioplasty (71) 170, (72) 483 Angiopoietin2 (72) 394 Angiotensin (71) 129, (72) 456 Angiotensin II (71) 247, (71) 794 Animal model (71) 179 Animal models (71) 586 Ankyrin (71) 22 ANP (72) 112 Antihypertensive (72) 184 Antihypertensive agents (71) 118 Antioxidant (72) 112 Antisense oligonucleotides (71) 352 Apoptosis (71) 118, (71) 139, (71) 466, (71) 754, (71) 774, (72) 51, (72) 163 Arrhythmia (71) 22, (71) 496, (72) 241 Arrhythmia (mechanisms) (71) 704, (72) 292, (72) 412 Arrhythmias (mechanisms) (71) 88 Arsenic trioxide (As 2 O 3 ) (72) 483 Arterial stiffness (72) 349 Arteries (71) 40, (72) 60 Atherosclerosis (71) 30, (71) 170, (71) 259, (71) 331, (71) 486, (71) 586, (71) 774, (72) 9, (72) 18, (72) 60, (72) 184, (72) 231, (72) 447 ATP release (71) 764 ATP-sensitive (71) 383 Atrial fibrillation (72) 69 Atrial myocardium (72) 69 Autonomic nervous system (71) 129, (72) 90 Axl tyrosine kinase receptor (71) 754 Azide (71) 30 Biochemistry (71) 79 Blood pressure (71) 247, (71) 596 Bone marrow (72) 175 Brugada syndrome (71) 22Ca 2+ -activated (71) 383 Ca 2+ channels (71) 630 Ca-channel (71) 310, (71) 496 Ca-pump (71) 310 Calcineurin (71) 672 Calcium (71) 300, (71) 715 Calcium (cellular) (72) 163, (72) 262 Calcium channel (71) 478, (72) 292 Capillary pressure (72) 41 Carbon monoxide (71) 393 Cardiac development (72) 198, (72) 364 Cardiac fibroblast (71) 280 Cardiac function (71) 69, (71) 557 Cardiac ischemia (72) 210 Cardiac morphogenesis (72) 198 Cardiac remodeling (72) 152 Cardiac remodelling (72) 198 Cardiac specification (72) 198 Cardiocyte (71) 506 Cardiomyocyte (71) 108, (71) 704, (72) 422 Cardiomyocytes (71) 10, (72) 112 Cardiomyopathy (71) 139, (71) 496, (72) 303 Cardioprotection (71) 672, (72) 313, (72) 322 Caveolin (71) 478 CD36 (72) 473 CDK2 (71) 61 Cell culture (71) 118, (71) 704 Cell differentiation (71) 158, (71) 170, (71) 661 Cell senescence (72) 9 Cell therapy (71) 158, (71) 419, (71) 744 Cellular signaling (72) 152 Chemoreflex (71) 129 Cholesterol (71) 443, (72) 438 Chronic heart failure (71) 443 Chronic obstructive pulmonary disease (72) 30 Computer modelling (71) 704 Conduction (72) 282 Conduction block (72) 282 Congenital defects (71) 50 Connective tissue (72) 375 Connexin43 (72) 412 Connexins (72) 69, (72) 282 Contractile function (71) 374, (71) 652, (72) 134, (72) 163, (72) 384 Contraction (71) 363, (72) 422 CORM-3 (71) 393 Coxsackievirus (71) 517 C-reactive protein (71) 30 CXCR4/SDF-1 axis (71) 455 Cytochromes (71) 195 Cytokines (71) 466, (71)
Correspondence
Authors: Robert L. Kane
Journal: JAMA (1977)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Do condom catheter collecting systems cause urinary tract infection?
Authors: D. D. Hirsh
Journal: JAMA (1979)

A study was undertaken to determine whether use of a condom catheter collection system (CCCS) is associated with urinary tract infection (UTI). No UTI developed in 79 episodes of CCCS use in patients who were cooperative or because of paralysis were unable to manipulate the collecting system (mean time per patient, 21.2 days; total number of patient days, 1,677). By contrast, in 15 patients who were identified prospectively as being uncooperative and who repeatedly manipulated the CCCS, UTI developed in eight (53.3%) within a mean of 9.6 days. Urethral catheterization in cooperative patients during CCCS use was followed by development of UTI. Repeated interference with the proper use of CCCS and urethral catheterization during CCCS use are associated with an increased risk of UTI. (<i>JAMA</i>242:340-341, 1979)
Suicide with, and because of, cocaine
Authors: K. Sperry
Journal: JAMA (1988)

<h3>To the Editor.</h3> —The proliferation of cocaine abuse has engendered an increase in deaths, emergency department visits, hospitalizations, and treatment programs. However, suicide with cocaine as the toxic agent has not yet, to my knowledge, been reported in the United States. In the past two years, two deaths from intentional intravenous cocaine use have been studied by autopsy by the New Mexico Office of the Medical Investigator. In each case, notes at the scene indicated that the primary reason for suicide was addiction to cocaine. <h3>Report of Cases.—Case 1.</h3> —A 25-year-old college student was found dead in his room, accompanied by insulin syringes, a spoon, and a piece of formed white granular material. The autopsy disclosed multiple fresh and healing intravenous injection sites involving both antecubital fossae, forearms, dorsal feet, and the medial ankles. A suicide note began, "I'm real sorry I had to do this but I
Transplantation immunology. Clinical aspects
Authors: C. H. Kirkpatrick
Journal: JAMA (1982)

ALTHOUGH transplantation of tissues is very artificial biologically, therapeutically it has provided a successful approach to management of functional failure of a variety of organs or systems. Renal transplantation is practiced widely in many centers throughout the world for patients with chronic renal failure for whom a suitable donor is available. Transplantation of bone marrow is becoming more widely practiced for aplastic anemia, immunodeficiency, and a variety of cancers, especially leukemia, as increasing numbers of centers for this procedure are created (see chapter 21). Transplantation of heart, liver, endocrine tissue, skin, lung, bone, and nonviable tissues is also practiced, but to a lesser extent, and is beyond the scope of this primer. <h3>TYPES OF GRAFTS</h3> Four types of transplants or grafts are recognized according to the genetic relationship between the donor and recipient (Table 19-1). An allograft is one transplanted between genetically nonidentical members of the same species, eg, all
CEREBRAL DECOMPRESSION.PALLIATIVE OPERATIONS IN THE TREATMENT OF TUMORS OF THE BRAIN.
Authors: WILLIAM G. SPILLER
Journal: JAMA (1906)

<h3>Case 11.</h3> —Tumor of cerebellum. <h3>History.</h3> —F., aged 16, was referred to Dr. Spiller, July 16, 1904, by Dr. J. S. Baer and Dr. R. G. Curtin. The father of the patient possibly had had syphilis. The menses ceased about two years ago; having begun when she was 14, they had, therefore, been present only a short time. For about one year she had had a severe sensation of pressure at the back of the head, as though some one were pressing her brain out, but this sensation is not felt now. She has had headache, not localized to any one part of the head, and has had "neuralgia" in the left side of the forehead about a year. Before December, 1903, the headache was severe. About a year ago she began to have nausea and vomiting, at first about every six weeks, but these symptoms gradually became more frequent